Skip Navigation


Brain Advance Access originally published online on September 30, 2007
Brain 2008 131(2):e89; doi:10.1093/brain/awm180
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
131/2/e89    most recent
awm180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nash, R. A.
Right arrow Articles by Muraro, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nash, R. A.
Right arrow Articles by Muraro, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Autologous HSCT for advanced MS: Is the glass half-empty or really half-full?

Richard A. Nash1,6, Olaf Stuve2, James D. Bowen3, Elliot M. Frohman2, Linda M. Griffith4, George J. Hutton5, George H. Kraft6, Uday Popat7, Michael K. Racke8 and Paolo A. Muraro9

1Fred Hutchinson Cancer Research Center, Seattle, WA, 2University of Texas Southwestern, Dallas, TX, 3MS Center at Evergreen, Evergreen Hospital Medical Center, Kirkland, WA, 4National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, 5Baylor College of Medicine, Houston, TX, 6University of Washington, Seattle, WA, 7MD Anderson Cancer Center, Houston, TX, 8Ohio State University, Columbus OH, USA and 9Imperial College, London, UK

Correspondence to: Richard A. Nash E-mail: rnash@fhcrc.org

Received June 11, 2007. Accepted July 9, 2007.

The first 10% of the full text of this article appears below.

Sir, On the basis of persisting demyelination and axonal degeneration in brains of patients with progressive multiple sclerosis (MS), Metz et al. (2007Go) concluded that ‘autologous hematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration’. This was based on routine and immunohistochemical stains of brains from five patients who died at a median of 2 (range 0.5–18) months after high-dose immunosuppressive therapy (HDIT) and autologous hematopoietic stem cell transplantation (HSCT). Although this small series of autopsy cases contributed significant and interesting insights, the conclusion . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch NeurolHome page
J.-Q. Lu, J. Storek, L. Metz, V. W. Yong, A. M. Stevens, R. A. Nash, and J. T. Joseph
Continued Disease Activity in a Patient With Multiple Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Arch Neurol, January 1, 2009; 66(1): 116 - 120.
[Abstract] [Full Text] [PDF]